<p>Forty years of Interferon I wish to dedicate this short introduction to the memory of Alick Isaacs (1921-1967), and to that of Sir Christopher Andrewes (1896-1988). Let us go back more than 40 years. In 1956 Isaacs was in charge of the Wodd Influenza Centre. Andrewes was head of the division of b
Recombinant Protein Drugs
β Scribed by Charles Weissmann (auth.), Peter Buckel (eds.)
- Publisher
- BirkhΓ€user Basel
- Year
- 2001
- Tongue
- English
- Leaves
- 206
- Series
- Milestones in Drug Therapy
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
Recombinant protein drugs are intimately associated with the impressive success story of the Biotech Industry during the past thirty years, some of them belonging to the most successful pharmaceutical products. More than thirty different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects of recombinant protein drug discovery and development are presented, covering past, present and future highlights. Leading scientists and co-founders of early Biotech companies describe technical breakthroughs and the fascinating story of pioneering discoveries, as well as the long way of translating them into products and business. Therefore, this book represents an exciting documentation of the beginning of a new era in the pharmaceutical industry. In addition, scientists from basic research, clinic and industry actively involved in new developments discuss...
β¦ Table of Contents
Front Matter....Pages I-X
Front Matter....Pages 1-1
Recombinant interferon - the 20th anniversary....Pages 3-41
Combining science and business: from recombinant DNA to vaccines against hepatitis B virus....Pages 43-64
Front Matter....Pages 65-65
Clotting factors VIII and IX....Pages 67-88
Colony-stimulating factors: altering the practice of oncology....Pages 89-106
Tissue-type plasminogen activator: helping patients with acute myocardial infarction....Pages 107-126
Front Matter....Pages 127-127
Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy....Pages 129-147
Front Matter....Pages 149-149
Improving protein therapeutics: the evolution of the modern pharmacopoeia....Pages 151-168
Principles of gene transfer and foreign protein expression for human gene therapy....Pages 169-180
Back Matter....Pages 181-207
β¦ Subjects
Medicine/Public Health, general
π SIMILAR VOLUMES
The rapidly evolving field of protein science has now come to realize the ubiquity and importance of protein-protein interactions. It had been known for some time that proteins may interact with each other to form functional complexes, but it was thought to be the property of only a handful of key p
<p>Gabriel Waksman Institute of Structural Molecular Biology, Birkbeck and University College London, Malet Street, London WC1E 7HX, United Kingdom Address for correspondence: Professor Gabriel Waksman Institute of Structural Molecular Biology Birkbeck and University College London Malet Street Lond
Univ. of Aberdeen, Scotland. Text providing comprehensive and detailed protocols covering all the latest molecular approaches. For new and established reseachers and biotechnoloists.
The latest edition of this highly acclaimed textbook, provides a comprehensive and up-to-date overview of the science and medical applications of biopharmaceutical products. Biopharmaceuticals refers to pharmaceutical substances derived from biological sources, and increasingly, it is synonymous wit
<p><p>This volume provides an overview of the main yeast production platforms currently used and future yeast cell factories for recombinant protein production. Chapters detail approaches of genetic and metabolic engineering, co-factor containing proteins and virus-like particles, glycoproteins, and